ABSTRACT
Objectives
To compare Wiltse approach‐based invasion‐controlled surgery (ICS) with traditional open surgery (TOS) for symptomatic thoracolumbar spinal metastases within the Neurologic, Oncologic, Mechanical, and Systemic (NOMS) framework, focusing on perioperative burden, postoperative recovery, neurological outcomes, pain, and QLQ‐BM22 domains.
Methods
This retrospective cohort study included 30 patients undergoing ICS and 60 patients undergoing TOS from January 25, 2019, to January 25, 2022. Perioperative, neurological, and patient‐reported outcomes were compared, including operative burden, postoperative recovery, complications, ASIA grade, VAS score, and QLQ‐BM22 domains. Continuous variables were assessed with Shapiro–Wilk tests and compared using two‐sided Welch independent‐samples t‐tests; categorical variables were analyzed using Pearson's χ 2 or exact tests, and Mann–Whitney U tests were used for sensitivity analyses when patient‐level data were available.
Results
The groups differed in preoperative ASIA distribution (p = 0.036). Compared with TOS, ICS was associated with shorter operative time (p < 0.001), lower blood loss (p = 0.005), lower transfusion volume (p < 0.001), less postoperative drainage (p = 0.021), earlier ambulation (p < 0.001), and a shorter interval to subsequent oncologic treatment (p < 0.001). The day‐1 leukocyte count was lower in the ICS group (p = 0.028), whereas C‐reactive protein was higher (p = 0.042). The overall complication frequency (p = 1.000), postoperative‐week‐2 ASIA distribution (p = 0.247), and favorable neurological outcome frequency (53.3% vs. 50.0%, p = 0.766) did not differ significantly between groups.
Conclusions
Wiltse approach‐based ICS was associated with reduced operative burden and faster postoperative recovery, without evidence of a worse postoperative neurological distribution in the unadjusted comparison. ICS may be considered a complementary muscle‐sparing option within NOMS‐guided management for appropriately selected patients who require posterior stabilization with decompression or separation.
Trial Registration: ClinicalTrials.gov identifier: ChiCTR1800016921.
Keywords: invasion‐controlled surgery, spinal metastases, traditional open surgery, Wiltse approach
Invasion‐controlled surgery via the Wiltse approach for thoracolumbar spine metastasis significantly reduces blood loss, shortens operation time, and accelerates postoperative radiotherapy, while maintaining neurological outcomes—optimizing tumor control under the NOMS framework.

1. Introduction
Spinal metastatic disease refers to metastatic involvement of the spinal column by malignancies originating outside the spine and represents one of the most clinically significant forms of metastatic bone disease [1, 2, 3]. Clinically diagnosed spinal metastases have been reported in approximately 15.7% of patients with solid tumors, while autopsy studies suggest that spinal involvement may be underestimated in clinical practice [1]. These lesions may cause severe pain, pathological fracture, metastatic epidural spinal cord compression, neurological deficits, and mechanical instability, thereby substantially impairing patients' functional status and quality of life [2, 3, 4, 5]. Metastatic spinal cord compression has been reported to develop in approximately 5.0%–10.0% of patients with cancer and represents one of the most serious spinal skeletal‐related events [5, 6, 7]. Once neurological impairment develops, timely intervention is critical for preserving ambulation and preventing irreversible functional decline. In a landmark randomized trial, direct decompressive surgery followed by radiotherapy improved the proportion of patients who retained or regained walking ability compared with radiotherapy alone in selected patients with metastatic spinal cord compression (84.0% vs. 57.0%, p < 0.001) [8]. Over the past decade, advances in stereotactic body radiotherapy (SBRT), systemic therapy, and multidisciplinary oncologic care have shifted the management of metastatic spinal disease from purely palliative intervention toward individualized strategies that balance neurological preservation, local tumor control, mechanical stability, and systemic tolerance [9, 10, 11]. In this context, the Neurologic, Oncologic, Mechanical, and Systemic (NOMS) framework provides a structured decision‐making model by integrating neurological involvement, tumor radiosensitivity, spinal stability, and the patient's systemic condition [11, 12, 13].
Within the NOMS framework, the role of surgery for spinal metastases has been redefined in the era of high‐precision radiotherapy. Rather than pursuing maximal tumor resection in all patients, surgery is increasingly used to achieve two essential goals: neural decompression and mechanical stabilization. Separation surgery was developed to reduce the grade of epidural spinal cord compression and to re‐establish a safe cerebrospinal fluid space between the tumor and the spinal cord or dural sac, thereby facilitating the delivery of postoperative high‐dose conformal radiotherapy or SBRT [11, 12, 14]. This treatment paradigm shifts the surgical objective from extensive tumor debulking toward limited but adequate decompression that supports subsequent oncologic treatment [11, 12, 14]. Clinical studies have shown that separation surgery followed by stereotactic radiosurgery or SBRT can provide durable local disease control in appropriately selected patients with metastatic epidural spinal cord compression [14, 15]. However, the safe delivery of SBRT requires careful adherence to spinal cord dose constraints, and adequate tumor–cord separation remains an important technical prerequisite for postoperative radiation planning [10, 16]. Several minimally invasive or less invasive strategies have been introduced to reduce surgical morbidity in patients with spinal metastases, including percutaneous pedicle screw fixation, vertebral augmentation, tubular decompression, endoscopic decompression, and minimal access separation surgery [17, 18, 19, 20, 21]. These techniques are valuable in selected patients, particularly when the main indications are pain control or mechanical stabilization without severe epidural spinal cord compression. However, they may be less suitable for patients with high‐grade epidural compression, progressive neurological deficits, circumferential epidural tumor involvement requiring 360° decompression or separation, or substantial intracanalar tumor burden requiring more complete epidural tumor removal. Therefore, a muscle‐sparing surgical strategy that can reduce approach‐related injury while maintaining adequate decompression and posterior stabilization remains clinically relevant. In this study, we adopted a Wiltse approach‐based muscle‐sparing separation surgery strategy, referred to as invasion‐controlled surgery. The Wiltse paraspinal approach uses the natural intermuscular plane between the multifidus and longissimus muscles, allowing access to the posterior elements and pedicle entry zones with less extensive paraspinal muscle stripping than the traditional posterior midline approach [22, 23, 24]. ICS should therefore be understood as a surgical strategy rather than a newly invented procedure or a replacement for established minimally invasive techniques. In this context, separation surgery defines the decompression goal, whereas ICS emphasizes how this goal may be achieved with less approach‐related tissue injury in appropriately selected patients.
Existing studies combine heterogeneous minimally invasive techniques, and direct comparative evidence for a Wiltse muscle‐sparing corridor used to meet NOMS‐defined stabilization and decompression goals remains limited. This evidence gap complicates procedure selection when adequate neural‐element decompression must be balanced against minimizing operative burden in medically vulnerable patients. Therefore, this retrospective exploratory cohort study aimed to compare perioperative outcomes, neurological recovery, pain, quality of life, complications, time to first ambulation, and the interval to subsequent postoperative oncologic treatment between Wiltse approach‐based ICS and traditional open surgery within the NOMS framework. We hypothesized that, in appropriately selected patients requiring posterior stabilization together with decompression or circumferential separation, Wiltse approach‐based ICS would be associated with reduced perioperative surgical burden and faster postoperative recovery without compromising neurological outcomes.
2. Methods
2.1. Study Design and Patients
This retrospective exploratory cohort study analyzed patients who underwent surgery for thoracolumbar spinal metastases at our institution between January 25, 2019, and January 25, 2022. Patients were treated with either Wiltse approach‐based invasion‐controlled surgery (ICS) or traditional open surgery (TOS) according to clinical symptoms, imaging findings, neurological status, spinal stability, systemic condition, and multidisciplinary assessment within the NOMS framework.
The study protocol was approved by the Institutional Ethics Review Board of our hospital (approval No. 2018SL0234) and was conducted in accordance with the Declaration of Helsinki. Written informed consent for surgery was obtained from all patients after detailed explanation of the surgical options, potential benefits, risks, and alternative treatment strategies. This study was prepared in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
During the study period, 30 eligible patients underwent Wiltse approach‐based ICS. Sixty‐three patients who had previously undergone TOS were initially screened as potential controls. To improve comparability between groups, TOS patients were selected according to predefined clinical criteria, including tumor histology, spinal region involved, and the extent of bony resection or decompression. After excluding three patients because of loss to follow‐up, 60 patients in the TOS group were included in the final analysis. The final cohort therefore consisted of 30 patients in the ICS group and 60 patients in the TOS group.
2.2. Inclusion and Exclusion Criteria
The study population included patients aged ≥ 18 years with histologically confirmed primary malignancies and radiologically confirmed thoracolumbar spinal metastases. Patients were considered eligible for surgery if they had one or more of the following indications: refractory pain attributable to spinal metastases, mechanical instability or a high risk of instability based on the Spinal Instability Neoplastic Score (SINS), progressive neurological deficits, or epidural spinal cord compression requiring decompression or separation of the neural elements. Before surgery and cohort inclusion, systemic condition and operative fitness were assessed through multidisciplinary review within the NOMS framework, including Eastern Cooperative Oncology Group (ECOG) performance status. ECOG performance status was used solely to inform preoperative surgical candidacy and was not treated as a longitudinal postoperative outcome.
Patients whose symptoms, spinal instability, or local tumor‐related complications could be adequately managed with conservative treatment, vertebral augmentation, radiotherapy, or systemic therapy alone were not included in the surgical cohort. Patients with cervical spinal metastases were excluded because the Wiltse paraspinal approach was applied only to thoracolumbar lesions in this study. Additional exclusion criteria included prior surgery at the responsible spinal level, primary spinal tumors, planned total en bloc spondylectomy, incomplete perioperative or follow‐up data, and severe systemic disease that precluded surgical treatment.
2.3. Data Collection and Outcome Measures
Demographic, clinical, imaging, perioperative, and follow‐up data were collected from the institutional medical record system and imaging database. Baseline variables included age, sex, primary tumor type, previous oncologic treatment, involved spinal region, neurological status, Spinal Instability Neoplastic Score (SINS), and Epidural Spinal Cord Compression (ESCC/Bilsky) grade. Neurological function was assessed using the American Spinal Injury Association (ASIA) impairment scale. Pain intensity and quality of life were assessed using the Visual Analog Scale (VAS) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Bone Metastases 22 (EORTC QLQ‐BM22), respectively.
Perioperative outcomes included operative time, intraoperative blood loss, transfusion requirement, postoperative drainage volume, postoperative inflammatory markers, perioperative complications, discharge disposition, time to first ambulation, length of hospital stay, and the interval to subsequent postoperative oncologic treatment. Postoperative inflammatory markers included leukocyte count (×109/L) and C‐reactive protein (mg/L) on postoperative day 1. The interval to subsequent postoperative oncologic treatment was defined as the time from surgery to the first postoperative radiotherapy, chemotherapy, targeted therapy, immunotherapy, or other indicated oncologic treatment.
Neurological improvement was defined as an improvement of at least one ASIA grade after surgery, whereas neurological deterioration was defined as a decrease of at least one ASIA grade. Maintenance of preoperative grade E was recorded separately. For the between‐group analysis, a favorable neurological outcome was defined as either improvement by at least one ASIA grade or maintenance of preoperative grade E. Postoperative ASIA grades were assessed at postoperative week 2. Perioperative complications were defined as adverse events occurring within 30 days after surgery that required medical intervention. VAS and EORTC QLQ‐BM22 assessments were performed preoperatively, at postoperative week 1, and at postoperative month 3.
2.4. Surgical Techniques
Patients in the ICS group underwent posterior surgery via a Wiltse paraspinal muscle‐sparing approach. This approach uses the natural intermuscular plane between the multifidus and longissimus muscles, allowing access to the posterior elements and pedicle entry zones with limited paraspinal muscle detachment. Posterior instrumentation was performed to restore or maintain stability, and neural decompression or separation was performed to the extent indicated by the neurological, oncologic, mechanical, and imaging findings. Pedicle screws were placed under fluoroscopic guidance, and epidural tumor was removed when decompression or separation was required. All included patients had SINS‐defined potential instability or instability. Therefore, in patients with ESCC grades 0–1c, low‐grade epidural disease alone was not the indication for surgery; stabilization was undertaken for the mechanical indication, and formal decompression or separation was added only when neurological, radicular, or oncologic factors required it. In the TOS group, a conventional midline posterior approach with subperiosteal paraspinal dissection was used, with the same decompression and stabilization goals (Figure 1).
FIGURE 1.

Key intraoperative steps and postoperative imaging of Wiltse approach–based invasion‐controlled surgery (ICS). (A) Limited midline skin incision centered over the tumor‐bearing vertebra, with preservation of the paraspinal musculature and fascia at non–tumor‐bearing levels. (B) Pedicle screw insertion through bilateral intermuscular corridors using the Wiltse approach at instrumented levels remote from the decompression zone. (C) Focused midline exposure at the target level with laminectomy when required for posterior decompression. (D, E) Intraoperative views after intralesional tumor debulking, showing the spinal canal and neural elements. (F) Postoperative anteroposterior and lateral radiographs showing multilevel posterior fixation. (G) Postoperative magnetic resonance imaging showing circumferential decompression in the illustrated case. ICS, invasion‐controlled surgery.
All procedures were performed by the same surgical team with experience in both ICS and TOS techniques. Intraoperative neuromonitoring was employed when appropriate. Hemostasis, instrumentation, and wound closure were performed according to standard institutional protocols. Postoperative care included routine drain management, early mobilization, and initiation of adjuvant therapy as clinically indicated.
2.5. Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics (IBM Corp., Armonk, NY, USA). Normality of continuous variables was evaluated using Shapiro–Wilk tests. Continuous variables were summarized as mean ± standard deviation and compared between groups using two‐sided Welch independent‐samples t‐tests. Because several variables with available patient‐level data departed from normality, Mann–Whitney U tests were conducted as sensitivity analyses; these analyses did not change the classification of the Table 1 or Table 3 comparisons as statistically significant or nonsignificant. Categorical variables were summarized as n (%) and compared using Pearson's χ 2 test when all expected cell counts were at least 5. When any expected cell count was below 5, Fisher's exact test was used for 2 × 2 tables and the Fisher–Freeman–Halton exact test was used for larger contingency tables. All tests were two‐sided. p‐values were reported to three decimal places, with values below 0.001 reported as p < 0.001; p < 0.05 was considered statistically significant.
TABLE 1.
Baseline demographic and clinical characteristics of the study groups.
| Characteristic | ICS group (n = 30) | TOS group (n = 60) | p |
|---|---|---|---|
| Demographic characteristics | |||
| Age, years | 58.27 ± 7.07 | 59.82 ± 6.27 | 0.314 |
| Sex, n (%) | 0.451 | ||
| Male | 11 (36.7) | 27 (45.0) | |
| Female | 19 (63.3) | 33 (55.0) | |
| Tumor and spinal disease characteristics | |||
| Primary tumor, n (%) | 0.988 | ||
| Lung | 12 (40.0) | 23 (38.3) | |
| Breast | 5 (16.7) | 9 (15.0) | |
| Liver | 6 (20.0) | 11 (18.3) | |
| Kidney | 3 (10.0) | 6 (10.0) | |
| Colon | 4 (13.3) | 11 (18.3) | |
| Main spinal level, n (%) | 0.758 | ||
| Thoracic | 18 (60.0) | 38 (63.3) | |
| Lumbar | 12 (40.0) | 22 (36.7) | |
| Preoperative ASIA grade, n (%) | 0.036 | ||
| B | 4 (13.3) | 10 (16.7) | |
| C | 14 (46.7) | 14 (23.3) | |
| D | 5 (16.7) | 26 (43.3) | |
| E | 7 (23.3) | 10 (16.7) | |
| ESCC grade, n (%) | 0.467 | ||
| 0 | 5 (16.7) | 6 (10.0) | |
| 1a | 4 (13.3) | 8 (13.3) | |
| 1b | 3 (10.0) | 15 (25.0) | |
| 1c | 9 (30.0) | 11 (18.3) | |
| 2 | 6 (20.0) | 15 (25.0) | |
| 3 | 3 (10.0) | 5 (8.3) | |
| SINS category, n (%) | 0.291 | ||
| Potentially unstable | 19 (63.3) | 31 (51.7) | |
| Unstable | 11 (36.7) | 29 (48.3) | |
| Baseline patient‐reported outcomes | |||
| VAS score | 5.77 ± 0.97 | 6.05 ± 1.14 | 0.223 |
| QLQ‐BM22 painful sites | 69.67 ± 9.09 | 66.58 ± 10.39 | 0.153 |
| QLQ‐BM22 pain characteristics | 60.28 ± 10.87 | 59.44 ± 10.79 | 0.732 |
| QLQ‐BM22 functional interference | 69.27 ± 4.93 | 67.45 ± 4.86 | 0.102 |
| QLQ‐BM22 psychosocial aspects | 54.67 ± 7.71 | 55.06 ± 7.50 | 0.821 |
Note: Data are presented as mean ± SD or n (%). Percentages may not total 100% because of rounding. Continuous variables were compared with two‐sided Welch independent‐samples t‐tests. Categorical variables were compared with Pearson's χ 2 test when all expected cell counts were ≥ 5 and with an exact test otherwise. p‐values are reported to three decimal places; values < 0.001 are shown as < 0.001. Normality was evaluated using Shapiro–Wilk tests. Mann–Whitney U sensitivity analyses were conducted for continuous variables with available patient‐level data and did not change their significance classification.
Abbreviations: ASIA, American Spinal Injury Association; ESCC, epidural spinal cord compression; ICS, invasion‐controlled surgery; QLQ‐BM22, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Bone Metastases 22; SD, standard deviation; SINS, Spinal Instability Neoplastic Score; TOS, traditional open surgery; VAS, visual analogue scale.
TABLE 3.
Neurological, pain, and quality‐of‐life outcomes.
| Characteristic | ICS group (n = 30) | TOS group (n = 60) | p |
|---|---|---|---|
| Neurological outcomes | |||
| ASIA grade at postoperative week 2, n (%) | 0.247 | ||
| C | 11 (36.7) | 13 (21.7) | |
| D | 12 (40.0) | 34 (56.7) | |
| E | 7 (23.3) | 13 (21.7) | |
| Favorable neurological outcome a , n (%) | 16 (53.3) | 30 (50.0) | 0.766 |
| Pain and quality of life at postoperative week 1 | |||
| VAS score | 4.03 ± 0.67 | 4.93 ± 0.73 | < 0.001 |
| QLQ‐BM22 painful sites | 50.17 ± 5.80 | 53.50 ± 7.55 | 0.023 |
| QLQ‐BM22 pain characteristics | 52.50 ± 7.31 | 63.89 ± 8.77 | < 0.001 |
| QLQ‐BM22 functional interference b | 59.06 ± 4.05 | 66.09 ± 5.33 | < 0.001 |
| QLQ‐BM22 psychosocial aspects b | 66.94 ± 14.68 | 75.14 ± 15.19 | 0.016 |
| Pain and quality of life at postoperative month 3 | |||
| VAS score | 3.63 ± 0.61 | 3.97 ± 0.71 | 0.025 |
| QLQ‐BM22 painful sites | 50.17 ± 5.65 | 53.33 ± 7.79 | 0.031 |
| QLQ‐BM22 pain characteristics | 43.61 ± 7.15 | 45.28 ± 9.25 | 0.349 |
| QLQ‐BM22 functional interference b | 58.96 ± 6.90 | 64.22 ± 8.08 | 0.002 |
| QLQ‐BM22 psychosocial aspects b | 64.58 ± 20.14 | 68.61 ± 18.02 | 0.359 |
Note: Data are presented as mean ± SD or n (%). No ASIA grade A or B was reported at postoperative week 2. Continuous variables were compared with two‐sided Welch independent‐samples t‐tests. Categorical variables were compared with Pearson's χ 2 test when all expected cell counts were ≥ 5 and with an exact test otherwise. Normality was evaluated using Shapiro–Wilk tests. Mann–Whitney U sensitivity analyses were conducted for continuous variables with available patient‐level data and did not change their significance classification.
Abbreviations: ASIA, American Spinal Injury Association; ICS, invasion‐controlled surgery; QLQ‐BM22, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Bone Metastases 22; SD, standard deviation; TOS, traditional open surgery; VAS, visual analogue scale.
Favorable neurological outcome at postoperative week 2 was defined as improvement by at least one ASIA grade or maintenance of preoperative grade E.
For QLQ‐BM22, lower Painful Sites and Pain Characteristics scores indicate fewer symptoms, whereas higher Functional Interference and Psychosocial Aspects scores indicate better functioning. Accordingly, the lower functional‐domain scores in the ICS group should not be described as better function.
3. Results
3.1. Baseline and Preoperative Characteristics
A total of 90 patients were included, comprising 30 patients in the ICS group and 60 in the TOS group. Table 1 summarizes the baseline characteristics. Age, sex, primary tumor distribution, main spinal level, ESCC grade, baseline VAS score, and baseline QLQ‐BM22 domain scores did not differ significantly between groups. In the TOS group, 38 patients (63.3%) had thoracic lesions and 22 (36.7%) had lumbar lesions. The preoperative ASIA distribution differed significantly (p = 0.036), with proportionally more grade C patients in the ICS group and more grade D patients in the TOS group.
3.2. Intraoperative and Postoperative Outcomes
Table 2 summarizes the intraoperative and postoperative outcomes. Compared with TOS, ICS was associated with a shorter operative time (p < 0.001), lower intraoperative blood loss (p = 0.005), lower transfusion volume (p < 0.001) and recipient frequency (p = 0.013), and lower postoperative drainage (p = 0.021), as well as shorter times to first ambulation, hospital discharge, and subsequent oncologic treatment (all p < 0.001). Intraoperative fluoroscopy did not differ significantly (p = 0.081). On postoperative day 1, the leukocyte count was lower in the ICS group (9.03 ± 2.55 vs. 10.43 ± 3.22 × 109/L; p = 0.028), whereas C‐reactive protein was higher (136.13 ± 17.53 vs. 128.05 ± 17.10 mg/L; p = 0.042); thus, the inflammatory markers did not show a uniform directional benefit. Complications were recorded in 3 of 30 ICS patients and 5 of 60 TOS patients (p = 1.000). One death was recorded in the ICS group after transfer to a rehabilitation facility; no death was recorded in the TOS group.
TABLE 2.
Intraoperative and postoperative outcomes.
| Characteristic | ICS group (n = 30) | TOS group (n = 60) | p |
|---|---|---|---|
| Intraoperative outcomes | |||
| Operation time, min | 167.83 ± 28.21 | 194.93 ± 20.55 | < 0.001 |
| Blood loss, mL | 886.67 ± 167.61 | 1000.83 ± 190.71 | 0.005 |
| Transfusion volume, mL | 200.00 ± 246.35 | 436.67 ± 326.24 | < 0.001 |
| Patients receiving transfusion, n (%) | 14 (46.7) | 44 (73.3) | 0.013 |
| Intraoperative fluoroscopy, times | 3.77 ± 1.30 | 3.27 ± 1.16 | 0.081 |
| Postoperative recovery | |||
| Drainage volume, mL | 377.60 ± 57.80 | 407.00 ± 49.75 | 0.021 |
| Time to first ambulation, days | 20.53 ± 2.92 | 25.23 ± 3.62 | < 0.001 |
| Length of hospital stay, days | 22.03 ± 4.02 | 26.88 ± 4.28 | < 0.001 |
| Time to subsequent oncologic treatment, days | 47.17 ± 7.24 | 63.27 ± 19.01 | < 0.001 |
| Postoperative inflammatory markers | |||
| Leukocyte count on postoperative day 1, ×109/L | 9.03 ± 2.55 | 10.43 ± 3.22 | 0.028 |
| C‐reactive protein on postoperative day 1, mg/L | 136.13 ± 17.53 | 128.05 ± 17.10 | 0.042 |
| Perioperative complications | |||
| Any complication, n (%) | 3 (10.0) | 5 (8.3) | 1.000 |
| Massive bleeding | 1 (3.3) | 1 (1.7) | |
| Surgical site infection | 1 (3.3) | 4 (6.7) | |
| Deep vein thrombosis | 1 (3.3) | 0 | |
| Postoperative disposition | |||
| Discharge/postoperative status a , n (%) | 0.215 | ||
| Returned home | 21 (70.0) | 48 (80.0) | |
| Transferred to another facility | 8 (26.7) | 12 (20.0) | |
| Death after transfer to rehabilitation a | 1 (3.3) | 0 | |
Note: Data are presented as mean ± SD or n (%). No epidural hemorrhage or instrumentation failure was reported in either group. Continuous variables were compared with two‐sided Welch independent‐samples t‐tests. Categorical variables were compared with Pearson's χ 2 test when all expected cell counts were ≥ 5 and with an exact test otherwise.
Abbreviations: CRP, C‐reactive protein; ICS, invasion‐controlled surgery; SD, standard deviation; TOS, traditional open surgery.
One death occurred in the ICS group after transfer to a rehabilitation facility; it was not an in‐hospital death. No death occurred in the TOS group.
3.3. Neurological and Patient‐Reported Outcomes
Postoperative neurological and patient‐reported outcomes are presented in Table 3. At postoperative week 2, the ASIA grade distribution did not differ significantly between groups (p = 0.247). A favorable neurological outcome—improvement by at least one ASIA grade or maintenance of preoperative grade E—occurred in 16 patients (53.3%) in the ICS group and 30 (50.0%) in the TOS group (p = 0.766). VAS scores were lower in the ICS group at postoperative week 1 (p < 0.001) and at postoperative month 3 (p = 0.025) (Figure 2). QLQ‐BM22 Painful Sites and Pain Characteristics scores were lower in the ICS group at postoperative week 1 (p = 0.023 and p < 0.001, respectively), indicating fewer symptoms; at postoperative month 3, only Painful Sites remained lower (p = 0.031) (Figure 3). Conversely, the ICS group had lower Functional Interference scores at both postoperative assessments (p < 0.001 and p = 0.002) and a lower Psychosocial Aspects score at postoperative week 1 (p = 0.016). Because higher scores on these functional domains indicate better functioning, these differences do not support superior functional quality of life in the ICS group. No unvalidated aggregate QLQ‐BM22 total score is reported.
FIGURE 2.

Pain intensity in the ICS and traditional open surgery (TOS) groups. Visual analogue scale (VAS) scores are shown preoperatively, at postoperative week 1, and at postoperative month 3. Values are mean ± standard deviation. Between‐group p‐values were calculated using two‐sided Welch independent‐samples t‐tests. VAS did not differ significantly at baseline (p = 0.223) and was lower in the ICS group at postoperative week 1 (p < 0.001) and postoperative month 3 (p = 0.025). Lower VAS scores indicate less pain. ICS, invasion‐controlled surgery; TOS, traditional open surgery; VAS, visual analogue scale. Mann–Whitney U sensitivity analyses of the available patient‐level VAS data did not change the significance classification.
FIGURE 3.

Quality‐of‐life outcomes assessed using the EORTC QLQ‐BM22 questionnaire. Quality‐of‐life domains evaluated included (A) total BM22 score, (B) painful sites, (C) pain characteristics, (D) functional interference, and (E) psychosocial functioning. Assessments were performed preoperatively, during the perioperative period, and at long‐term follow‐up. Patients treated with invasion‐controlled surgery demonstrated significantly better perioperative and long‐term outcomes in pain‐related and functional domains compared with those undergoing traditional open surgery, while psychosocial functioning showed no significant long‐term difference between groups. ICS indicates invasion‐controlled surgery; TOS, traditional open surgery. Asterisks indicate statistically significant intergroup differences (p < 0.05).
4. Discussion
4.1. Principal Findings
In the present retrospective exploratory cohort, Wiltse approach‐based invasion‐controlled surgery (ICS) was associated with reduced perioperative surgical burden compared with traditional open surgery (TOS), including shorter operative time, reduced intraoperative blood loss, lower transfusion requirement, and decreased postoperative drainage. The postoperative‐week‐2 ASIA grade distribution and favorable neurological outcome frequency did not differ significantly between groups; however, these unadjusted comparisons should be interpreted in light of the baseline ASIA imbalance. These findings support interpreting ICS primarily as an approach‐related, muscle‐sparing modification within the broader concept of separation surgery rather than as a newly invented decompression technique. For appropriately selected patients requiring posterior stabilization with decompression or separation, ICS may provide a less disruptive route to achieve NOMS‐guided surgical objectives [22, 23, 24].
4.2. Surgical Strategy and Indications Within the NOMS Framework
A plausible explanation is that the Wiltse paraspinal corridor allows access through the natural intermuscular plane between the multifidus and longissimus muscles, thereby reducing the need for wide midline muscle detachment and prolonged paraspinal retraction [22, 23, 24]. This distinction is important because, within the NOMS framework, separation surgery defines the decompression target, whereas ICS emphasizes how this target may be achieved with less approach‐related tissue injury [11, 12, 14]. Previous studies of minimally invasive or less invasive surgery for metastatic spinal disease have similarly reported reductions in blood loss and perioperative morbidity compared with traditional open procedures, although surgical indications and techniques vary across studies [17, 18]. Thus, the present findings support the role of Wiltse approach‐based ICS as a muscle‐sparing modification of separation surgery for selected patients who require posterior stabilization and adequate neural decompression, rather than as a replacement for established percutaneous, endoscopic, or vertebral augmentation techniques. Recent NOMS updates, systematic reviews, comparative studies, and SBRT evidence emphasize multidisciplinary procedure selection and caution against treating heterogeneous minimally invasive techniques as interchangeable [25, 26, 27, 28, 29, 30].
It is important to place Wiltse approach‐based ICS within the broader spectrum of minimally invasive strategies for metastatic spinal disease. Percutaneous pedicle screw fixation, vertebral augmentation, tubular decompression, endoscopic decompression, and minimal access separation surgery have all been used to reduce surgical morbidity in appropriately selected patients [17, 18]. Percutaneous fixation may provide mechanical stabilization with less posterior soft‐tissue exposure, whereas vertebral augmentation may be useful for pain control and vertebral body support in selected metastatic lesions [20, 21]. These techniques may be particularly useful when the primary indication is pain control or mechanical stabilization, especially in patients without high‐grade epidural spinal cord compression or progressive neurological deficit [11, 12, 17, 18]. For selected patients with low‐grade epidural disease, including some cases of Bilsky/ESCC grade 1c compression with preserved neurological function, percutaneous stabilization, vertebral augmentation, or radiotherapy‐based treatment without formal decompression may be reasonable [11, 12, 18].
However, the indication for surgery in metastatic spinal disease should not be determined by radiographic grade alone. Neurological status, mechanical instability, refractory mechanical pain, tumor radiosensitivity, systemic tolerance, expected survival, and the feasibility of timely postoperative radiotherapy should be integrated within the NOMS framework [11, 12]. Low‐grade ESCC therefore does not itself exclude surgery when an independent mechanical or clinical indication is present, but it also does not automatically justify formal decompression. In this cohort, 21 of 30 ICS patients and 40 of 60 TOS patients had ESCC grades 0–1c, and all participants had at least SINS‐defined potential instability. Thus, the low‐grade cases remained eligible principally because of a mechanical indication; decompression or separation was added only when separately indicated. For patients with high‐grade epidural compression, progressive neurological deterioration, circumferential epidural tumor, or substantial intracanalar tumor burden, purely percutaneous stabilization or vertebral augmentation may be insufficient [11, 12, 14]. In this setting, Wiltse approach‐based ICS may serve as a complementary muscle‐sparing strategy that allows posterior stabilization and adequate decompression through a less disruptive paraspinal corridor [22, 23, 24]. A recent multicenter prospective SINS study likewise supports individualized stabilization decisions rather than relying on a radiographic threshold alone [31].
4.3. Perioperative Burden and Inflammatory Response
The perioperative profile observed in this study suggests that the operative corridor may influence recovery‐related outcomes in patients undergoing stabilization with decompression or separation as indicated. The shorter operative time, lower intraoperative blood loss, reduced transfusion requirement, and lower postoperative drainage volume in the ICS group are consistent with the expected effect of limiting paraspinal muscle detachment and reducing approach‐related soft‐tissue exposure [22, 23, 24]. These findings are clinically relevant because patients with spinal metastases often have impaired systemic reserve, anemia, malnutrition, tumor‐related inflammation, or ongoing systemic therapy, all of which may reduce tolerance to prolonged surgery and perioperative blood loss [2, 3, 4]. Previous studies of minimal access surgery for metastatic spinal tumors have similarly suggested that reducing approach‐related tissue disruption may decrease blood loss and perioperative morbidity, although the magnitude of benefit varies according to tumor vascularity, spinal level, extent of decompression, and instrumentation requirements [17, 18, 20].
However, these perioperative associations should be interpreted cautiously. Although the postoperative‐day‐1 leukocyte count was lower in the ICS group, C‐reactive protein was higher; therefore, the inflammatory‐marker results do not support a uniform reduction in systemic inflammatory response. Moreover, the overall complication frequency did not differ significantly between groups. These findings suggest that the principal observed value of the muscle‐sparing approach lies in selected measures of operative burden and recovery rather than elimination of the intrinsic perioperative risks of metastatic spine surgery. Recent prospective, NSQIP, performance‐status, and registry studies further emphasize individualized patient selection and careful monitoring of perioperative adverse events in this population [32, 33, 34, 35].
4.4. Neurological and Patient‐Reported Outcomes
Neurological preservation remains a central objective of surgery for metastatic spinal disease. In this cohort, the postoperative‐week‐2 ASIA distribution and favorable neurological outcome frequency did not differ significantly, although the unadjusted comparison is limited by the baseline ASIA imbalance. VAS and the symptom‐oriented QLQ‐BM22 Painful Sites and Pain Characteristics domains favored ICS at postoperative week 1. By contrast, lower Functional Interference and Psychosocial Aspects scores represent worse, not better, functioning under standard QLQ‐BM22 scoring. Therefore, the patient‐reported outcomes show a mixed domain‐specific pattern and do not support a claim of uniform or sustained quality‐of‐life superiority. Recent prospective, longitudinal, and prediction‐model studies likewise support reporting domain‐specific, time‐specific patient‐reported outcomes after surgery for spinal metastases [36, 37, 38, 39].
4.5. Recovery and Readiness for Subsequent Oncologic Treatment
In multidisciplinary management, the value of surgery depends not only on decompression and stabilization but also on recovery and readiness for subsequent oncologic treatment [11, 12]. In this cohort, the ICS group had shorter times to first ambulation and to the first subsequent postoperative oncologic treatment. Earlier mobilization may reduce bed‐rest–related complications and support functional recovery, while an earlier return to radiotherapy or systemic treatment may support continuity of care [17, 18]. However, the study was not designed to determine whether these timing differences improve local control, progression‐free survival, or overall survival.
At the same time, this finding should be interpreted cautiously. Earlier ambulation or faster postoperative recovery does not necessarily translate into improved local tumor control or survival, and these endpoints were not fully assessed in the present cohort. Therefore, the clinical significance of Wiltse approach‐based ICS should be understood as supporting recovery and subsequent treatment readiness within a multidisciplinary treatment pathway, rather than as direct evidence of improved oncologic outcomes. Future studies should evaluate whether reduced approach‐related surgical burden can improve adherence to planned postoperative radiotherapy or systemic therapy and whether this translates into durable functional or oncologic benefit.
4.6. Strengths and Limitations
The study has several strengths: the comparison was framed using explicit NOMS‐based indications; all procedures were performed by the same experienced surgical team; and perioperative, neurological, pain, and domain‐specific QLQ‐BM22 outcomes were examined together. Exact tests were used for sparse categorical data, and sensitivity analyses were performed for continuous outcomes when patient‐level data were available.
Several limitations should be acknowledged. First, this was a retrospective single‐center cohort with a relatively small ICS sample and unequal group sizes. Although most measured baseline characteristics appeared similar, the preoperative ASIA distribution was imbalanced; selection bias, residual confounding, and limited statistical power therefore cannot be excluded. Second, follow‐up was limited, and long‐term oncologic and implant‐related outcomes, including local tumor control, survival, late instrumentation failure, and delayed complications, were not fully assessed. The findings should therefore be interpreted as exploratory and hypothesis‐generating rather than definitive evidence of superiority. Prospective multicenter studies with larger cohorts and longer follow‐up are needed to validate these results and clarify the optimal indications for Wiltse approach‐based ICS among the broader spectrum of minimally invasive strategies for spinal metastases.
5. Conclusions
For patients selected within the NOMS framework who required posterior stabilization with decompression or separation as indicated, Wiltse approach‐based ICS achieved the intended surgical objectives with shorter operative time, less blood loss and transfusion, less postoperative drainage, earlier ambulation, and an earlier return to subsequent oncologic treatment than TOS. Neurological and overall complication outcomes were not significantly different in the unadjusted comparisons, and QLQ‐BM22 results were mixed across domains. ICS should therefore be considered a complementary muscle‐sparing option rather than evidence of oncologic superiority; prospective multicenter validation is required.
Author Contributions
Jiawei Zhou: data curation, investigation. Hao Yuan: formal analysis. Wei Xu: writing – review and editing, supervision, project administration, funding acquisition. Gan Xu: validation. Meiling Xu: software, writing – review and editing, resources. Jianru Xiao: conceptualization, project administration. Pengru Wang: conceptualization, writing – original draft. Zhilong Shen: methodology, software.
Funding
This work was supported by the Science and Technology Commission of Shanghai Municipality (23Y11903600) and Naval Medical University (Second Military Medical University) (SL30 and JXPY2023B08).
Disclosure
The authors have nothing to report.
Ethics Statement
The study protocol was approved by the Institutional Ethics Review Board of our hospital (approval No. 2018SL0234) and was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. The study was registered in the Chinese Clinical Trial Registry (ChiCTR1800016921).
Consent
All patients were fully informed about the surgical treatment methods, risks, and potential complications and signed an informed consent form.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
This work was supported by the Doctor assistance program at the Naval Medical University (Second Military Medical University) (SL30 and JXPY2023B08). We gratefully acknowledge the patients who participated in this study and the clinical staff who contributed to patient care and data collection.
Contributor Information
Jianru Xiao, Email: jianruxiao83@163.com.
Wei Xu, Email: xuwei_spine@163.com.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1. Van Den Brande R., Cornips E. M., Peeters M., et al., “Epidemiology of Spinal Metastases, Metastatic Epidural Spinal Cord Compression and Pathologic Vertebral Compression Fractures in Patients With Solid Tumors: A Systematic Review,” Journal of Bone Oncology 35 (2022): 100446. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Coleman R. E., “Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity,” Clinical Cancer Research 12, no. 20 Pt 2 (2006): 6243s–6249s. [DOI] [PubMed] [Google Scholar]
- 3. Macedo F., Ladeira K., Pinho F., et al., “Bone Metastases: An Overview,” Oncology Reviews 11, no. 1 (2017): 321. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Kaloostian P. E., Yurter A., Zadnik P. L., Sciubba D. M., and Gokaslan Z. L., “Current Paradigms for Metastatic Spinal Disease: An Evidence‐Based Review,” Annals of Surgical Oncology 21, no. 1 (2014): 248–262. [DOI] [PubMed] [Google Scholar]
- 5. Cole J. S. and Patchell R. A., “Metastatic Epidural Spinal Cord Compression,” Lancet Neurology 7, no. 5 (2008): 459–466. [DOI] [PubMed] [Google Scholar]
- 6. Byrne T. N., “Spinal Cord Compression From Epidural Metastases,” New England Journal of Medicine 327, no. 9 (1992): 614–619. [DOI] [PubMed] [Google Scholar]
- 7. Schmidt M. H., P. Klimo, JR. , and Vrionis F. D., “Metastatic Spinal Cord Compression,” Journal of the National Comprehensive Cancer Network 3, no. 5 (2005): 711–719. [DOI] [PubMed] [Google Scholar]
- 8. Patchell R. A., Tibbs P. A., Regine W. F., et al., “Direct Decompressive Surgical Resection in the Treatment of Spinal Cord Compression Caused by Metastatic Cancer: A Randomised Trial,” Lancet 366, no. 9486 (2005): 643–648. [DOI] [PubMed] [Google Scholar]
- 9. Sahgal A., Ames C., Chou D., et al., “Stereotactic Body Radiotherapy Is Effective Salvage Therapy for Patients With Prior Radiation of Spinal Metastases,” International Journal of Radiation Oncology, Biology, Physics 74, no. 3 (2009): 723–731. [DOI] [PubMed] [Google Scholar]
- 10. Thibault I., Chang E. L., Sheehan J., et al., “Response Assessment After Stereotactic Body Radiotherapy for Spinal Metastasis: A Report From the SPIne Response Assessment in Neuro‐Oncology (SPINO) Group,” Lancet Oncology 16, no. 16 (2015): e595–e603. [DOI] [PubMed] [Google Scholar]
- 11. Barzilai O., Laufer I., Yamada Y., et al., “Integrating Evidence‐Based Medicine for Treatment of Spinal Metastases Into a Decision Framework: Neurologic, Oncologic, Mechanicals Stability, and Systemic Disease,” Journal of Clinical Oncology 35, no. 21 (2017): 2419–2427. [DOI] [PubMed] [Google Scholar]
- 12. Laufer I., Rubin D. G., Lis E., et al., “The NOMS Framework: Approach to the Treatment of Spinal Metastatic Tumors,” Oncologist 18, no. 6 (2013): 744–751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Newman W. C., Laufer I., and Bilsky M. H., “Neurologic, Oncologic, Mechanical, and Systemic and Other Decision Frameworks for Spinal Disease,” Neurosurgery Clinics of North America 31, no. 2 (2020): 151–166. [DOI] [PubMed] [Google Scholar]
- 14. Laufer I., Iorgulescu J. B., Chapman T., et al., “Local Disease Control for Spinal Metastases Following “Separation Surgery” and Adjuvant Hypofractionated or High‐Dose Single‐Fraction Stereotactic Radiosurgery: Outcome Analysis in 186 Patients,” Journal of Neurosurgery. Spine 18, no. 3 (2013): 207–214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Ito K., Sugita S., Nakajima Y., et al., “Phase 2 Clinical Trial of Separation Surgery Followed by Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord Compression,” International Journal of Radiation Oncology, Biology, Physics 112, no. 1 (2022): 106–113. [DOI] [PubMed] [Google Scholar]
- 16. Sahgal A., Weinberg V., Ma L., et al., “Probabilities of Radiation Myelopathy Specific to Stereotactic Body Radiation Therapy to Guide Safe Practice,” International Journal of Radiation Oncology, Biology, Physics 85, no. 2 (2013): 341–347. [DOI] [PubMed] [Google Scholar]
- 17. Barzilai O., Bilsky M. H., and Laufer I., “The Role of Minimal Access Surgery in the Treatment of Spinal Metastatic Tumors,” Global Spine Journal 10, no. 2 Suppl (2020): 79s–87s. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Zuckerman S. L., Laufer I., Sahgal A., et al., “When Less Is More: The Indications for MIS Techniques and Separation Surgery in Metastatic Spine Disease,” Spine 41, no. Suppl 20 (2016): S246–s53. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Kumar N., Tan J. H., Thomas A. C., et al., “The Utility of 'Minimal Access and Separation Surgery' in the Management of Metastatic Spine Disease,” Global Spine Journal 13, no. 7 (2023): 1793–1802. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Kumar N., Malhotra R., Maharajan K., et al., “Metastatic Spine Tumor Surgery: A Comparative Study of Minimally Invasive Approach Using Percutaneous Pedicle Screws Fixation Versus Open Approach,” Clinical Spine Surgery 30, no. 8 (2017): E1015–E1021. [DOI] [PubMed] [Google Scholar]
- 21. Sadeghi‐Naini M., Aarabi S., Shokraneh F., et al., “Vertebroplasty and Kyphoplasty for Metastatic Spinal Lesions: A Systematic Review,” Clinical Spine Surgery 31, no. 5 (2018): 203–210. [DOI] [PubMed] [Google Scholar]
- 22. Wiltse L. L., Bateman J. G., Hutchinson R. H., et al., “The Paraspinal Sacrospinalis‐Splitting Approach to the Lumbar Spine,” Journal of Bone and Joint Surgery. American Volume 50, no. 5 (1968): 919–926. [PubMed] [Google Scholar]
- 23. Wiltse L. L. and Spencer C. W., “New Uses and Refinements of the Paraspinal Approach to the Lumbar Spine,” Spine 13, no. 6 (1988): 696–706. [PubMed] [Google Scholar]
- 24. Vialle R., Wicart P., Drain O., et al., “The Wiltse Paraspinal Approach to the Lumbar Spine Revisited: An Anatomic Study,” Clinical Orthopaedics and Related Research 445 (2006): 175–180. [DOI] [PubMed] [Google Scholar]
- 25. Newman W. C., Larsen A. G., and Bilsky M. H., “The NOMS Approach to Metastatic Tumors: Integrating New Technologies to Improve Outcomes,” Revista Española de Cirugía Ortopédica y Traumatología 67, no. 6 (2023): 487–499. [DOI] [PubMed] [Google Scholar]
- 26. Schupper A. J., Patel S., Steinberger J. M., et al., “The Role of Minimally Invasive Surgery Within a Multidisciplinary Approach for Patients With Metastatic Spine Disease Over a Decade: A Systematic Review,” Neuro‐Oncology 26, no. 3 (2024): 417–428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Cui Y., Mi C., Wang B., et al., “Mini‐Open Compared With the Trans‐Tubular Approach in Patients With Spinal Metastases Undergoing Decompression Surgery: A Retrospective Cohort Study,” BMC Cancer 23, no. 1 (2023): 1226. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Suvithayasiri S., Kim Y. J., Liu Y., et al., “The Role and Clinical Outcomes of Endoscopic Spine Surgery for Treating Spinal Metastases: Outcomes of 29 Cases From 8 Countries,” Neurospine 20, no. 2 (2023): 608–619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Shakil H., Essa A., Malhotra A. K., et al., “Perioperative Outcomes After Minimally Invasive and Open Surgery for Treatment of Spine Metastases: A Systematic Review and Meta‐Analysis,” Journal of Neurosurgery: Spine 42, no. 2 (2025): 215–229. [DOI] [PubMed] [Google Scholar]
- 30. Koide Y., Haimoto S., Shimizu H., et al., “Re‐Irradiation Spine Stereotactic Body Radiotherapy Following High‐Dose Conventional Radiotherapy for Metastatic Epidural Spinal Cord Compression: A Retrospective Study,” Japanese Journal of Radiology 42, no. 6 (2024): 662–672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Nakajima H., Watanabe S., Honjoh K., et al., “Surgical Strategy for Metastatic Spinal Tumors Based on Spine Instability Neoplastic Score and Patient‐Reported Outcomes: JASA Multicenter Prospective Study,” Journal of Neurosurgery. Spine 42, no. 2 (2025): 203–214. [DOI] [PubMed] [Google Scholar]
- 32. Yakdan S. M., Herrera M., Wehbe N., et al., “Outcome of Spine Surgery in the Context of Spinal Metastatic Disease: The National Surgical Quality Improvement Program,” Journal of Craniovertebral Junction and Spine 15, no. 4 (2024): 499–505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Kanda Y., Kakutani K., Sakai Y., et al., “Clinical Characteristics, Surgical Outcomes, and Risk Factors for Emergency Surgery in Patients With Spinal Metastases: A Prospective Cohort Study,” Neurospine 21, no. 1 (2024): 314–327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Lenschow M., Lenz M., Telentschak S., et al., “Preoperative Performance Status Threshold for Favorable Surgical Outcome in Metastatic Spine Disease,” Neurosurgery 95, no. 4 (2024): 770–778. [DOI] [PubMed] [Google Scholar]
- 35. Barbanti Brodano G., Griffoni C., Salamanna F., et al., “Evaluation of Adverse Events and the Impact on Health‐Related Outcomes in Patients Undergoing Surgery for Metastatic Spine Tumors: Analysis of the MTRON Registry Dataset,” Global Spine Journal 16, no. 1 (2026): 410–433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Barzilai O., Sahgal A., Rhines L. D., et al., “Patient‐Reported and Clinical Outcomes of Surgically Treated Patients With Symptomatic Spinal Metastases: Results From EPOSO, a Prospective, Multi‐Institutional and International Study,” Neurosurgery 95, no. 5 (2024): 1148–1157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Segi N., Nakashima H., Ito S., et al., “Effects of Palliative Surgical Treatment for Spinal Metastases on Quality of Life With a Focus on the Segment of Metastasis: A Prospective Multicenter Study,” Global Spine Journal 15, no. 4 (2025): 2286–2299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38. Terzi S., Griffoni C., Rosa S., et al., “Health‐Related Quality of Life After Surgery for Spinal Metastases,” Journal of Bone Oncology 52 (2025): 100675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Kuijten R. H., Bindels B., Groot O., et al., “Predicting Quality of Life of Patients After Treatment for Spinal Metastatic Disease: Development and Internal Evaluation,” Spine Journal 25, no. 7 (2025): 1371–1385. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
